NLRP3 and cardiac hypertrophy: Knockdown of NLRP3 with siRNA or pharmaceutical inhibition of NLRP3 inflammasome activation reverses myocardial hypertrophy markers and myocardial fibrosis-associated protein expression both in vivo and in vitro [57, 58].